Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J Schore

Showing results (11-20 of 28) with videos related to

Pageof 3
Sort By:
Cancer|November 8, 2017
Longitudinal analysis of quality-of-life outcomes in children during treatment for acute lymphoblastic leukemia: A report from the Children's Oncology Group AALL0932 trialDaniel J Zheng, Xiaomin Lu, Reuven J Schore, et al.
Pediatric Blood & Cancer|September 20, 2025
Caregivers' Perspectives on Changes in Family Life During B-ALL Therapy: A Qualitative Study From the Children's Oncology GroupAlexandra Dreyzin, Megan Ware, Katrina Stumbras, et al.
Leukemia|February 16, 2020
Significance of minimal residual disease in pediatric mixed phenotype acute leukemia: a multicenter cohort studyMatthew J Oberley, Sunil S Raikar, Gerald B Wertheim, et al.
Pediatric Blood & Cancer|January 5, 2026
Diminished Quality of Life Despite Reduced Treatment in Children With B-Lymphoblastic Leukemia: Children's Oncology Group AALL0932Lyn M Balsamo, John A Kairalla, Emily Hibbitts, et al.
Journal of the National Cancer Institute|May 13, 2022
Persistence of Chemotherapy-Induced Peripheral Neuropathy Despite Vincristine Reduction in Childhood B-Acute Lymphoblastic LeukemiaRozalyn L Rodwin, John A Kairalla, Emily Hibbitts, et al.
Blood Advances|April 15, 2026
Adding Induction Intrathecal Cytarabine in Newly Diagnosed CNS2 B-Acute Lymphoblastic Leukemia Does Not Improve OutcomesCathy A Lee-Miller, John A Kairalla, Emily Hibbitts, et al.
Pediatric Blood & Cancer|February 9, 2021
Prognostic impact of minimal residual disease at the end of consolidation in NCI standard-risk B-lymphoblastic leukemia: A report from the Children's Oncology GroupRachel E Rau, Yunfeng Dai, Meenakshi Devidas, et al.
Pediatric Blood & Cancer|August 17, 2023
Assessment of proxy-reported responses as predictors of motor and sensory peripheral neuropathy in children with B-lymphoblastic leukemiaRozalyn L Rodwin, Natalie J DelRocco, Emily Hibbitts, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 29, 2014
Pharmacokinetic and pharmacodynamic properties of calaspargase pegol Escherichia coli L-asparaginase in the treatment of patients with acute lymphoblastic leukemia: results from Children's Oncology Group Study AALL07P4Anne L Angiolillo, Reuven J Schore, Meenakshi Devidas, et al.
Blood Advances|May 5, 2026
Toxicity from asparaginase during acute lymphoblastic leukemia induction: A report from the Children's Oncology GroupEtan Orgel, Luke D Maese, Meenakshi Devidas, et al.
Pageof 3

Showing results (11-20 of 28) with videos related to

Sort By:
Pageof 3
Cancer|November 8, 2017
Longitudinal analysis of quality-of-life outcomes in children during treatment for acute lymphoblastic leukemia: A report from the Children's Oncology Group AALL0932 trialDaniel J Zheng, Xiaomin Lu, Reuven J Schore, et al.
Pediatric Blood & Cancer|September 20, 2025
Caregivers' Perspectives on Changes in Family Life During B-ALL Therapy: A Qualitative Study From the Children's Oncology GroupAlexandra Dreyzin, Megan Ware, Katrina Stumbras, et al.
Leukemia|February 16, 2020
Significance of minimal residual disease in pediatric mixed phenotype acute leukemia: a multicenter cohort studyMatthew J Oberley, Sunil S Raikar, Gerald B Wertheim, et al.
Pediatric Blood & Cancer|January 5, 2026
Diminished Quality of Life Despite Reduced Treatment in Children With B-Lymphoblastic Leukemia: Children's Oncology Group AALL0932Lyn M Balsamo, John A Kairalla, Emily Hibbitts, et al.
Journal of the National Cancer Institute|May 13, 2022
Persistence of Chemotherapy-Induced Peripheral Neuropathy Despite Vincristine Reduction in Childhood B-Acute Lymphoblastic LeukemiaRozalyn L Rodwin, John A Kairalla, Emily Hibbitts, et al.
Blood Advances|April 15, 2026
Adding Induction Intrathecal Cytarabine in Newly Diagnosed CNS2 B-Acute Lymphoblastic Leukemia Does Not Improve OutcomesCathy A Lee-Miller, John A Kairalla, Emily Hibbitts, et al.
Pediatric Blood & Cancer|February 9, 2021
Prognostic impact of minimal residual disease at the end of consolidation in NCI standard-risk B-lymphoblastic leukemia: A report from the Children's Oncology GroupRachel E Rau, Yunfeng Dai, Meenakshi Devidas, et al.
Pediatric Blood & Cancer|August 17, 2023
Assessment of proxy-reported responses as predictors of motor and sensory peripheral neuropathy in children with B-lymphoblastic leukemiaRozalyn L Rodwin, Natalie J DelRocco, Emily Hibbitts, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 29, 2014
Pharmacokinetic and pharmacodynamic properties of calaspargase pegol Escherichia coli L-asparaginase in the treatment of patients with acute lymphoblastic leukemia: results from Children's Oncology Group Study AALL07P4Anne L Angiolillo, Reuven J Schore, Meenakshi Devidas, et al.
Blood Advances|May 5, 2026
Toxicity from asparaginase during acute lymphoblastic leukemia induction: A report from the Children's Oncology GroupEtan Orgel, Luke D Maese, Meenakshi Devidas, et al.
Pageof 3